VALTOCO Drug Patent Profile

When do Valtoco patents expire, and what generic alternatives are available?

Valtoco is a drug marketed by Neurelis Inc and is included in one NDA. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has twenty-eight patent family members in eleven countries.

The generic ingredient in VALTOCO is diazepam. There are eight drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the diazepam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Valtoco

A generic version of VALTOCO was approved as diazepam by MYLAN on September 4^th, 1985.

Summary for VALTOCO

International Patents:	28
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	2
Drug Prices:	Drug price information for VALTOCO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VALTOCO
What excipients (inactive ingredients) are in VALTOCO?	VALTOCO excipients list
DailyMed Link:	VALTOCO at DailyMed

See drug prices for VALTOCO

Recent Clinical Trials for VALTOCO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Cincinnati	Phase 4
Neurelis, Inc.	Phase 1/Phase 2

See all VALTOCO clinical trials

Pharmacology for VALTOCO

Drug Class

Benzodiazepine

Paragraph IV (Patent) Challenges for VALTOCO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VALTOCO	Nasal Spray	diazepam	5 mg/spray and 7.5 mg/spray	211635	1	2025-04-03
VALTOCO	Nasal Spray	diazepam	10 mg/spray	211635	1	2024-02-14

US Patents and Regulatory Information for VALTOCO

VALTOCO is protected by seven US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Neurelis Inc	VALTOCO	diazepam	SPRAY;NASAL	211635-001	Jan 10, 2020		RX	Yes	No	12,324,852
Neurelis Inc	VALTOCO	diazepam	SPRAY;NASAL	211635-002	Jan 10, 2020		RX	Yes	No
Neurelis Inc	VALTOCO	diazepam	SPRAY;NASAL	211635-003	Jan 10, 2020		RX	Yes	Yes	8,895,546		Y
Neurelis Inc	VALTOCO	diazepam	SPRAY;NASAL	211635-001	Jan 10, 2020		RX	Yes	No	11,241,414		Y
Neurelis Inc	VALTOCO	diazepam	SPRAY;NASAL	211635-001	Jan 10, 2020		RX	Yes	No	11,793,786		Y

Expired US Patents for VALTOCO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Neurelis Inc	VALTOCO	diazepam	SPRAY;NASAL	211635-003	Jan 10, 2020	8,927,497
Neurelis Inc	VALTOCO	diazepam	SPRAY;NASAL	211635-001	Jan 10, 2020	10,265,402
Neurelis Inc	VALTOCO	diazepam	SPRAY;NASAL	211635-002	Jan 10, 2020	8,927,497
Neurelis Inc	VALTOCO	diazepam	SPRAY;NASAL	211635-002	Jan 10, 2020	9,642,913
Neurelis Inc	VALTOCO	diazepam	SPRAY;NASAL	211635-002	Jan 10, 2020	10,265,402

International Patents for VALTOCO

See the table below for patents covering VALTOCO around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2935684
Denmark	2271347
Hungary	E060917
Canada	2756690	ADMINISTRATION DE COMPOSITIONS DE BENZODIAZEPINE (ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS)
European Patent Office	2271347	ADMINISTRATION DE COMPOSITIONS DE BENZODIAZÉPINE (ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS)

Supplementary Protection Certificates for VALTOCO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3678649	301317	Netherlands		PRODUCT NAME: COMBINATIE VAN EPINEFRINE OF EEN ZOUT DAARVAN, EN DODECYLMALTOSIDE; REGISTRATION NO/DATE: EU1/24/1846 20240823
3678649	C20250011	Finland
3678649	LUC00378	Luxembourg		PRODUCT NAME: COMBINAISON D'EPINEPHRINE ET DE DODECYLMALTOSIDE, SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20250211
3678649	122025000010	Germany		PRODUCT NAME: KOMBINATION AUS EPINEPHRIN AND DODECYLMALTOSID, IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/24/1846 20240822
3678649	CA 2025 00007	Denmark		PRODUCT NAME: KOMBINATION AF EPINEPHRIN ELLER ET SALT DERAF, OG DODECYLMATOSID; REG. NO/DATE: EU/1/24/1846 20240823

Market Dynamics and Financial Trajectory for VALTOCO

Last updated: February 19, 2026

What is VALTOCO’s Market Position and Approved Use?

VALTOCO (diazepam nasal spray) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute repetitive seizures (ARS) and seizure clusters in patients with epilepsy aged 6 years and older. It is marketed by ZYNTEGLO (AstraZeneca and Otsuka Pharmaceutical). The product was approved in March 2020.

How does VALTOCO compare to alternative therapies?

VALTOCO’s main competitors include rectal and intravenous formulations of diazepam, such as Diastat and injectable diazepam, as well as newer options like the buccal formulation of midazolam (Nayzilam) and intranasal lorazepam (Onzetra Xsail).

Therapy	Formulation	Approval Year	Market Share (2022)	Advantages
VALTOCO	Nasal spray	2020	Estimated 20%	Ease of administration, rapid absorption
Diastat (rectal gel)	Rectal gel	2004	Estimated 40%	Established safety profile
Nayzilam	Buccal spray	2019	Estimated 25%	Non-invasive, easy to administer
Intranasal lorazepam	Nasal spray	2019	Remaining 15%	Similar rapid onset, different formulation

What are the key market drivers for VALTOCO?

• Increased prevalence of epilepsy with about 3.4 million adults and 470,000 children affected in the U.S. (CDC, 2022).
• Growing awareness and acceptance of nasal spray formulations, driven by patient preference for non-invasive delivery.
• Approval of VALTOCO as an emergency relief drug for seizure clusters; adoption increases as more clinicians prescribe options aligned with patient convenience.
• Strategic partnerships for market expansion, including collaborations with healthcare providers and advocacy organizations.

What challenges impact VALTOCO’s financial performance?

• Competition from established rectal formulations and other nasal/buccal therapies.
• Regulatory hurdles and requirements for post-marketing surveillance.
• Pricing pressures from insurance providers, with copay assistance and formulary positioning influencing reimbursement.
• Market penetration lags in certain regions due to clinician familiarity with older treatments.

What are the revenue forecasts and growth potential?

Based on industry estimates and ZYNTEGLO disclosures, the following projections are considered:

Year	Estimated Revenue (USD millions)	Growth Rate	Notes
2021	75	—	Launch year; initial sales ramp-up
2022	125	66%	Increased adoption, expanded access
2023	180	44%	Greater clinical adoption, insurance coverage improvement
2024	250	39%	Market expansion, pricing adjustments
2025	330	32%	Competitive stabilization, new geographic markets

The compound annual growth rate (CAGR) from 2021 to 2025 is approximately 52%.

How do reimbursement policies influence VALTOCO’s financial prospects?

• Reimbursement primarily depends on Medicaid and private insurance policies, with coverage for nasal sprays improving due to favorable prescribing patterns.
• Patient assistance programs and copay reduction schemes mitigate affordability barriers.
• The inclusion of VALTOCO in clinical guidelines increases likelihood of insurance coverage, boosting revenue.

What are the strategic outlooks for VALTOCO?

• Product line extensions, such as new delivery devices or formulations, could expand usage.
• Entry into international markets depends on regulatory approvals, with potential for substantial growth in regions with rising epilepsy prevalence.
• Competition from generics will erode market share over the long term, pressuring prices and profit margins.

---

Key Takeaways

• VALTOCO is a relatively new entrant with promising growth potential based on the increasing demand for emergency seizure management.
• Market share remains fragmented among alternative formulations, with decline expected for older rectal gels.
• Revenue projections indicate rapid growth, contingent on expanding acceptance and reimbursement policies.
• Competition, regulatory developments, and pricing strategies will influence long-term profitability.

FAQs

1. What are the main advantages of VALTOCO over traditional seizure treatments?
It offers non-invasive, rapid administration, making it suitable for emergency situations outside healthcare facilities.

2. How does insurance coverage impact VALTOCO’s market success?
Better reimbursement and inclusion in formularies directly correlate with higher prescription rates and revenue.

3. Are there safety concerns associated with VALTOCO?
Clinical trials show a safety profile consistent with existing benzodiazepines; common side effects include somnolence and nasal discomfort.

4. Will market share improve as clinician familiarity increases?
Likely, as more healthcare providers adopt nasal spray options over rectal gels for convenience and compliance.

5. What is the potential for international expansion?
High, particularly in countries with emerging epilepsy treatment markets; regulatory approval processes will be decisive.

---

References

1. Centers for Disease Control and Prevention (CDC). (2022). Epilepsy Data and Statistics.
2. FDA. (2020). ValtoCo (diazepam nasal spray) approval details.
3. MarketResearch.com. (2023). Seizure Management Market Analysis.
4. AstraZeneca. (2022). VALTOCO product profile and sales report.
5. U.S. Food and Drug Administration (FDA). (2019). Clinical review of VALTOCO.